Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Journal of the American Chemical Society|April 22, 2004
o-Iodoxybenzoic acid (IBX) as a viable reagent in the manipulation of nitrogen- and sulfur-containing substrates: scope, generality, and mechanism of IBX-mediated amine oxidations and dithiane deprotectionsK C Nicolaou, Casey J N Mathison, Tamsyn MontagnonJournal of the American Chemical Society|June 16, 2005
The total synthesis of coleophomones B, C, and DK C Nicolaou, Tamsyn Montagnon, Georgios Vassilikogiannakis, et al.Inorganic Chemistry|November 11, 2003
Copper(I) complexes of a heavily fluorinated beta-diketiminate ligand: synthesis, electronic properties, and intramolecular aerobic hydroxylationDavid S Laitar, Casey J N Mathison, William M Davis, et al.ACS Medicinal Chemistry Letters|June 22, 2019
Discovery of Orally Active Hydroxyethylamine Based SPPL2a InhibitorsJuraj Velcicky, Casey J N Mathison, Victor Nikulin, et al.Communications Biology|July 9, 2025
Triggering AHR resolves TGF-β1 induced fibroblast activation and promotes AT1 cell regeneration in alveolar organoidsAndrew S Hagan, Scott Williams, Casey J N Mathison, et al.ACS Medicinal Chemistry Letters|December 17, 2021
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-d]pyrimidine RET InhibitorsCasey J N Mathison, Yang Yang, John Nelson, et al.ACS Medicinal Chemistry Letters|April 16, 2020
Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung AdenocarcinomaCasey J N Mathison, Donatella Chianelli, Paul V Rucker, et al.Nature|August 9, 2016
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sicknessShilpi Khare, Advait S Nagle, Agnes Biggart, et al.Journal of Medicinal Chemistry|July 16, 2020
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of LeishmaniasesAdvait Nagle, Agnes Biggart, Celine Be, et al.Journal of Medicinal Chemistry|May 19, 2026
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical ValidationDean P Phillips, Phil B Alper, Charles Y Cho, et al.Pageof 1